Citius Pharmaceuticals Inc
NASDAQ:CTXR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.68
3.63
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 15 full-time employees. The company went IPO on 2017-08-03. The firm develops and commercializes critical care products with a focus on anti-infective products in adjunct cancer care, prescription products and mesenchymal stem cell therapy. The company has five products: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. Halo-Lido is a corticosteroid-lidocaine topical formulation, which is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. NoveCite is a mesenchymal stem cell therapy for the treatment of ARDS. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 15 full-time employees. The company went IPO on 2017-08-03. The firm develops and commercializes critical care products with a focus on anti-infective products in adjunct cancer care, prescription products and mesenchymal stem cell therapy. The company has five products: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. Halo-Lido is a corticosteroid-lidocaine topical formulation, which is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. NoveCite is a mesenchymal stem cell therapy for the treatment of ARDS. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.
